-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Foghorn Therapeutics Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2019 to Q3 2024.
- Foghorn Therapeutics Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $4.73M, a 36.2% increase year-over-year.
- Foghorn Therapeutics Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $14.9M, a 11.5% increase year-over-year.
- Foghorn Therapeutics Inc. annual Nonoperating Income (Expense) for 2023 was $13.7M, a 66% increase from 2022.
- Foghorn Therapeutics Inc. annual Nonoperating Income (Expense) for 2022 was $8.26M.
- Foghorn Therapeutics Inc. annual Nonoperating Income (Expense) for 2021 was -$586K, a 118% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)